Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Tan Tock Seng Hospital
Trial Status: Ongoing, Recruiting
Principal Investigator(s):
Dr Chan Wai Kay Johan
Dr Alvin Wong Seng Cheong
Dr Chia Puey Ling
Published by HT Digital Content Services with permission from Health Daily Digest....